Drug monitoring was conducted for rifapentine among people with HIV receiving dolutegravir containing antiretroviral therapy and latent tuberculosis treatment

The proportion of trough plasma concentration of dolutegravir (DTG) above protein adjusted 90 % inhibition concentration (IC90) (0.064 mg/L) was 98.1 % across all visits during the twelve doses of once-weekly rifapentine and isoniazid (3HP) in people with HIV (PWH). Furthermore, the participants maintained a high rate of HIV viral suppression (98 %) within 6 months after completing 3HP.